Skip to content

Diathermy Effectiveness in Reducing Subcutaneous Adipose Tissue Affected by Lipedema

Diathermy Effectiveness in Reducing Subcutaneous Adipose Tissue Affected by Lipedema

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05944796
Acronym
EDRTASAL
Enrollment
20
Registered
2023-07-13
Start date
2024-05-01
Completion date
2024-08-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema

Keywords

Lipedema

Brief summary

Diathermy, a therapy that uses deep heat to reach deep tissue layers, is known to induce the breaking down of fatty cells and fibrotic tissue. In lipedema, patients develop fibrosis of their subcutaneous adipose tissue. Therefore, diathermy could be an interesting tool to treat this disease. To test the effectiveness of diathermy on these patients, the investigators will select women with lipedema (18 to 70 yo) and place them in two groups (experimental and control group). The experimental group will receive the treatment, that is, 10 minutes of diathermy on the medial knee surface of both knees, with an intensity that produces heat just below the participants' pain threshold. Participants from the control group will receive sham diathermy, that is, placebo. The intervention consists of 10 sessions, 3 times a week, for 4 weeks. Researchers will collect data pre and post intervention and one month after the intervention ends. Data will consist of measurements at knee level with tape and an ultrasound device, pain threshold with an algometer, a VAS score and an SF-12 questionnaire for quality of life.

Detailed description

The goal of this clinical trial is to test the effectiveness of diathermy in reducing the subcutaneous adipose tissue affected by lipedema in women suffering from this disorder. The main questions it aims to answer are: * Does diathermy produce changes in subcutaneous adipose tissue affected by lipedema? * Is it effective as a tool for lipolysis and/or fibrolysis of said subcutaneous adipose tissue affected by lipedema? * Do these changes result in a reduction of subcutaneous adipose tissue affected by lipedema? * Do these changes decrease pain in the area treated with diathermy? Participants will: * Be assesed prior to receiving treatment: * Circometry of both knees (at joint space level) * Pain threshold using an algometer. Area: medial below knee region, at fibular head level * SF-12 questionnaire * VAS score * Ultrasound mesurements at medial collateral ligament (distance from skin to ligament) * Receive 10 diathermy sessions. 10 minutes per knee (medial knee surface), 3 times a week for 4 weeks. Parameters: 470 KHz, capacitive head, intensity: heat below pain threshold. * Be assesed after receiving treatment: * Circometry of both knees (at joint space level) * Pain threshold using an algometer. Area: medial below knee region, at fibular head level * SF-12 questionnaire * VAS score * Ultrasound mesurements at medial collateral ligament (distance from skin to ligament) * Be assesed after receiving treatment (one month post intervention): * Circometry of both knees (at joint space level) * Pain threshold using an algometer. Area: medial below knee region, at fibular head level * SF-12 questionnaire * VAS score * Ultrasound mesurements at medial collateral ligament (distance from skin to ligament) Researchers will compare an experimental group to a placebo group to see if treatment with diathermy is effective in reducing subcutaneous adipose tissue affected by lipedema.

Interventions

The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)

OTHERPlacebo

The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)

Sponsors

Camilo Jose Cela University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* women between 18-70 years old. * Diagnosed with lipedema by a medical service. * Patients with type III or V lipedema (involvement of legs). * Patients with type II lipedema are also admitted if they have a fat pad on the inner side of the knee

Exclusion criteria

* Pregnant * Pacemaker or some other electronic implant * Metal implants or knee prostheses * Open wounds or burns on the inside of the knee * Thrombophlebitis * Malignant growths (cancer) * Infectious processes * Follow other non-conservative treatment related to lipedema at that time

Design outcomes

Primary

MeasureTime frameDescription
Contour change in the knee.baselineBy using a tape measure, the circummetry of the knees on both sides will be assessed. The greater the contour, the more volume the patient will show.
Change of adipose tissue in the kneebaselineUsing ultrasound, it is intended to know if a reduction in adipose tissue has occurred after the application of diathermy.
Quality of life (SF-12).baselineSF-12 quality of life questionnaire. The higher the score obtained in the questionnaire, the better the patient's quality of life. The maximum value that can be reached is 100 and the minimum is 0.
Measure painbaselineVisual analogic scale (VAS). The higher the visual analogue scale score, the more pain the patient presents. The maximum value that can be reached is 10 and the minimum is 0.
Algometry.baselineUsing the algometer, pain sensitivity will be assessed when pressing medial infracondylar leg at the level of the fibular head. The lower the algometry score, the more pain the patient will have. The maximum value that can be reached is 5 and the minimum value is 0.

Secondary

MeasureTime frameDescription
Sociodemographic variablesbaseline.Sociodemographic data such as age, weight, height and marital status will be collected

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026